Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer

Abstract

Background/Aims: Smart molecular probes are required in the application of Magnetic resonance imaging (MRI) for biochemical and clinical research. This study aims to investigate the diagnostic values of estrogen receptor (ER), progesterone receptor (PR), folate receptor (FR) and human epidermal growth factor receptor 2 (HER-2)-targeted molecular probes in the MRI diagnosis of breast cancer. Methods: Initially, a total of 508 female breast cancer patients were selected for breast cancer subtype classification by immunohistochemistry. Subsequently, the tumor size, lymph node metastasis, and histological grade of different breast cancer subtypes were compared. Molecular probes of Ab-ER-USPIO, Ab-PR-USPIO, Ab-FR-USPIO and Ab-HER-2-USPIO were constructed and screened. The specific binding of molecular probes to breast cancer cells was detected both in vitro and in vivo by Prussian blue staining and MRI using T1 and T2 weighted images. Finally, in vivo toxicity of Ab-HER-2-USPIO was analyzed using hematoxylin and eosin staining. Results: We identified the following subtypes of breast cancer: Luminal A (ER-positive, FR-positive, HER-2-negative), Luminal B (ER-positive, FRpositive, HER-2-positive), HER-2 overexpression (ER-negative, FR-negative, HER-2-positive), and triple-negative breast cancer (ER-negative, FR-negative, HER-2-negative). Featuring favorable in vitro biocompatibility and low in vivo toxicity, Ab-HER-2-USPIO can specifically bind to breast cancer cells BT47 and SKBR3, thus enhancing the quality of T1 weighted MRI images. Conclusion: The results indicate that HER-2-targeted MRI molecular probes may be used in the clinical diagnosis of breast cancer and facilitate the development of promising strategies for breast cancer treatments.

Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry

“…Globally, ~1.7 million females are diagnosed with BC annually, resulting in >500,000 mortalities annually, which makes BC the most common malignant tumor type affecting the lives and health of females, not only in USA, but also globally in 2012 (5). At present, BC treatment primarily includes surgery, chemotherapy, endocrine therapy, radiotherapeutics and biotherapy (6,7). Nevertheless, the incidence and mortality of BC remain high, and BC still affects the quality of life of females (8).…”

AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion

“…Breast cancer (BC) is a type of malignant tumor that occurs in the epithelial tissue of the mammary gland, and approximately 99% of breast cancers occur in women [1, 2]. Breast cancers are usually classified into estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), or triple-negative breast cancer (TNBC) [3]. About 20% of breast cancers are an overexpression of HER2, a gene correlated with more aggression compared with other subtypes [4, 5].…”

Correlation between Histopathological Molecular Markers and Magnetic Resonance Imaging of Spiculated Breast Cancers

“…Yüksek ÖR veya PR pozitif oranları, HER2 negatifliği ve düşük Ki67 indeksini içeren çeşitli faktörlerin spikülasyonun oluşmasına katkıda bulunduğuna inanılmaktadır [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] . Liu S ve ark.…”

“…Patolojik olarak, bu moleküler subtipler tümör belirteçlerinin ekspresyon durumuna göre kategorize edilir: Östrojen reseptörü (ÖR), progesteron reseptörü (PR), HER2 ekspresyonu ve Ki-67 indeksi 5 . Meme kanserinin moleküler alt tiplendirilmesi, bireyselleştirilmiş hastaya özel tedavi planlaması için temel bir gereksinim haline gelmiştir 6 . Radyojenomik, görüntüleme özelliklerini moleküler profillerle ilişkilendirmeyi amaçlayan yeni bir araştırma alanıdır 7 .…”